Physician profile
Gregory Emili
NPI 1932287042
$3,061.02
in general payments reported to CMS, 2019-2025
31 companies · $875 in 2025
The $875 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $225 · 2021: $488 · 2022: $476 · 2023: $138 · 2024: $485 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $723.00 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $424.41 | 2019-2025 | Ztlido |
| Astellas Pharma US INC | $191.12 | 2025 | Veozah |
| Pfizer INC. | $163.49 | 2019-2025 | |
| Viiv Healthcare Company | $157.55 | 2019-2024 | Dovato |
| Biohaven Pharmaceutical Holding Company LTD. | $144.25 | 2022 | |
| Collegium Pharmaceutical, INC. | $136.81 | 2019-2023 | Xtampza |
| Orexo US, INC. | $119.25 | 2022-2023 | Zubsolv |
| Redhill Biopharma INC. | $101.00 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $93.00 | 2021 | |
| Forte Bio-Pharma LLC | $89.98 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Indivior INC. | $84.32 | 2021 | |
| Ardelyx, INC. | $83.33 | 2025 | Ibsrela |
| Emd Serono, INC. | $73.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $62.73 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $49.45 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $44.31 | 2019-2023 | Fasenra |
| Ibsa Pharma INC. | $39.79 | 2021-2023 | Tirosint, Licart |
| Horizon Therapeutics Plc | $37.68 | 2021-2022 | |
| Valinor Pharma, LLC | $32.41 | 2025 | Movantik |
| Vertex Pharmaceuticals Incorporated | $29.94 | 2025 | |
| Gilead Sciences, INC. | $28.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.67 | 2019 | |
| Exact Sciences Corporation | $22.64 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $18.21 | 2022 | |
| Shionogi INC | $16.66 | 2019 | |
| Abbvie INC. | $16.08 | 2025 | |
| Amarin Pharma, INC. | $15.73 | 2019 | |
| Novo Nordisk INC | $13.84 | 2023 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $12.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Emili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.